Cardiovascular Research Foundation announces late-breaking trials for TCT conference

The Cardiovascular Research Foundation has announced the lineup of late-breaking clinical trials and first report investigations for the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference.

The conference is taking place from Oct. 29 to Nov. 2 at the Walter E. Washington convention center in Washington, D.C. Here are the late-breaking clinical trials and first report investigations:

Sunday, Oct. 30 – late-breaking clinical trials

9:00 a.m. – ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease – presenter is Ziad A. Ali, MD, DPhil, an assistant professor of medicine at New York-Presbyterian/Columbia University Medical Center

9:20 a.m. – BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients with Coronary Artery Disease – presenter is Clemens von Birgelen, MD, PhD, a professor at Thoraxcentrum Twente in Enschede, The Netherlands

9:40 a.m. – BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs. a Zotarolimus-Eluting Stent in a More-Comers Population of Patients with Coronary Artery Disease – presenter is David E. Kandzari, MD, director of interventional cardiology research at the Piedmont Heart Institute in Atlanta

Sunday, Oct. 30 – first report investigations

12:15 p.m. – ABSORB China: Two-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease – presenter is Runlin Gao, a professor at Fu Wai Hospital in Beijing, China

12:30 p.m. – ABSORB II: Three-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease – presenter is Patrick W. Serruys, MD, PhD, a professor at Imperial College in London and the Thoraxcenter of Erasmus University in Rotterdam, The Netherlands

12:45 p.m. – LEADERS FREE: Two-Year Clinical and Subgroup Outcomes from a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients with Coronary Artery Disease at High Bleeding Risk – presenter is Philip M. Urban, MD, director of invasive cardiology at La Tour Hospital in Geneva, Switzerland

Monday, Oct. 31 – late-breaking clinical trials

9:00 a.m. – EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease – presenter is Gregg W. Stone, MD, director of cardiovascular research and education at New York-Presbyterian Hospital/Columbia University Medical Center

9:15 a.m. – NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease – presenter is Evald H. Christiansen, MD, PhD, of Aarhus University Hospital in Denmark

Monday, Oct. 31 – first report investigations

12:00 p.m. – REVELUTION: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes with a Polymer-Free Sirolimus-Eluting Drug-Filled Stent – presenter is Stephen G. Worthley, MBBS, PhD, of GenesisCare Pty Ltd in Alexandria, Australia

12:13 p.m. – FANTOM II: 6-Month and 9-Month Clinical, Angiographic and OCT Results with a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Alexandre Abizaid, MD, PhD, of Instituto Dante Pazzanese de Cardiologia in São Paulo, Brazil

12:21 p.m. – MeRes-1: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Ashok Seth, MBBS, of Fortis Escorts Heart Institute in New Delhi, India

12:29 p.m. – FORTITUDE: 9-Month Clinical, Angiographic, and OCT Results with an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Antonio Colombo, MD, director of the cardiac catheterization laboratory at Columbus Hospital/San Raffaele Hospital in Milan, Italy

12:37 p.m. – FUTURE-I: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Bo Xu, MD, director of the catheterization laboratory at Fu Wai Hospital in Beijing, China

Tuesday, Nov. 1 – late-breaking clinical trials

9:00 a.m. – SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement – presenter is Susheel Kodali, MD, of New York-Presbyterian/Columbia University Medical Center

9:20 a.m. – PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate Risk Patients with Severe Aortic Stenosis – presenter is David J. Cohen, MD, director of cardiovascular research at Saint Luke’s Mid America Heart Institute in Kansas City, Missouri

9:40 a.m. – PARTNER I FIVE-YEAR ECHO: Long-Term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Aortic Stenosis – presenter is Pamela S. Douglas, MD, of the Duke Clinical Research Institute in Durham, North Carolina

Tuesday, Nov. 1 – first report investigations

12:15 p.m. – RESPECT: Final Long-Term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke – presenter is David E. Thaler, MD, PhD, of Tufts Medical Center in Boston

12:30 p.m. – COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes after Stent Implantation in Patients with Coronary Artery Disease – presenter is Giora Weisz, MD, of Shaare Zedek Medical Center in Jerusalem, Israel

12:45 p.m. – PLATINUM DIVERSITY: Outcomes from a Large-Scale, Prospective Registry of Coronary Artery Stent Implantation in Women and Minorities – presenter is Wayne B. Batchelor, MD, of Tallahassee Memorial HealthCare in Tallahassee, Florida

1:00 p.m. – ReACT: A Prospective, Randomized Trial of Routine Angiographic Follow-up After Coronary Artery Stent Implantation – presenter is Hiroki Shiomi, MD, of Kyoto University Hospital in Kyoto, Japan

Wednesday, Nov. 2 – late-breaking clinical trials

9:00 a.m.ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries – presenter is Sean P. Lyden, MD, of the Cleveland Clinic Foundation

9:20 a.m. – WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation – presenter is Vivek Y. Reddy, MD, of Mount Sinai Medical Center in New York

9:40 a.m. – AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation – presenter is David Hildick-Smith, MD, of Sussex Cardiac Center at Brighton and Sussex University Hospitals in Brighton, United Kingdom

Wednesday, Nov. 2 – first report investigations

12:15 p.m. – PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients with Coronary Artery Chronic Total Occlusions – presenter is Koen Teeuwen, MD, of St. Antonius Hospital in Nieuwegein, The Netherlands

12:30 p.m. – TOSCA-5: A Prospective, Randomized Trial Evaluating Collagenase Infusion in Patients with Coronary Artery Chronic Total Occlusions – presenter is Christopher E. Buller, MD, director of cardiac cath and intervention at St. Michael’s Hospital in Toronto, Canada

12:45 p.m. – TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at 3 Months and Neoatherosclerosis at 18 Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents – presenter is Giulio Guagliumi, MD, of Ospedale Giovanni XXIII in Bergamo, Italy

1:00 p.m. – RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis – 6-9 Month Clinical and Angiographic Follow-up Results – presenter is Fernando Alfonso, MD, PhD, head of the cardiac department at Hospital Universitario de la Princesa in Madrid, Spain

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup